Duodenal metastasis of testicular cancer is an uncommon condition in clinical practice. Here, we have reported a case of this nature. Testicular cancers are among the most seen cancer types among young men. Metastasis of testicular cancer generally occurs through hematogenous and lymphatic drainage. Gastrointestinal (GI) metastasis of testicular cancer has been reported rarely. A duodenal mass was seen in esophagogastroduodenoscopic examination in a man who was admitted into hospital for medical treatment of resistant nausea and vomiting. He was previously diagnosed with testicular cancer. Computed tomography (CT) views were compatible with primary duodenal tumor. The duodenal mass was compatible with germ cell neoplasm metastasis. He received chemotherapy regime which includes cisplatin, paclitaxel, and ifosfamid. Nausea and vomiting symptoms decreased and metastatic mass and lymph nodes were regressed. Duodenum metastasis of testicular cancer can be treated with a chemotherapy regimen, and patients can improve radiologically and symptomatically without the need of any surgery. Physicians should keep in mind that GI metastasis of testicular cancer may present with nausea and vomiting symptoms. Duygulu ME, Kaymazli M, Goren I, Yildirim B, Sullu Y, Nural MS, Bektas A. Embryonal Testicular Cancer with Duodenal Metastasis: Could Nausea and Vomiting be Alarm Symptoms? Euroasian J Hepato-Gastroenterol 2016;6(2):198-201.
1 January 2024 in Revista da Associação Médica Brasileira
Large cell neuroendocrine carcinoma of the lung is a rare type of lung cancer. There is a limited number of studies on clinical and histopathological characteristics that are effective in survival. The aim of this study was to investigate the relationship between histopathological and clinical characteristics, mainly Ki-67 proliferation index, and survival in patients diagnosed with large cell neuroendocrine carcinoma of the lung. The data of 38 patients followed up with the diagnosis of large cell neuroendocrine carcinoma of the lung were evaluated. The mean Ki-67 value was determined to be 65.8% (±20.8). The patients' clinical characteristics and survival times were compared according to the cut-off value determined for Ki-67 index. When median overall survival times were compared, it was seen that overall survival was numerically lower in patients aged 65 years and over, in tumors located on the right side, in cases who were in the metastatic stage at diagnosis, whose Ki-67 index was 65% and above, who did not receive chemotherapy, who did not undergo curative surgery, and in patients with chronic diseases (p>0.05). In the Kaplan-Meier analysis, the median overall survival was determined to be 22.2 months (95%CI 21.7-22.7) in the patients with Ki-67<65%, while it was found to be 20.3 months (95%CI 4.5-36.2) in the patients with Ki-67≥65% (p=0.351). Our study identified subgroups with decreased survival in large cell neuroendocrine carcinoma of lung patients. Studies including a larger number of patients are needed to identify the prognostic importance of these clinical and histopathological characteristics.
Background and Objectives: Our study aimed to investigate the effect of RAS and TP53 mutations, either alone or in combination, on survival in patients with metastatic colorectal carcinoma (mCRC). Materials and Methods: Patients diagnosed with mCRC and followed up at our center between January 2019 and November 2023, who underwent somatic mutation analysis via next-generation sequencing (NGS) testing, were retrospectively evaluated. A total of 155 patients were evaluated within the scope of the study. Patients were grouped as mutant type (m) or wild type (w) for RAS and TP53. Survival times between the groups were examined using the Kaplan–Meier method. Cox regression analysis was performed for factors with a prognostic effect on survival. Results: Among the patients, 35.4% exhibited an RASm/TP53w mutation profile, 30.9% had RASw/TP53w, 20% had RASw/TP53m, and 13.5% had RASm/TP53m. The lowest median progression-free survival (mPFS) and median overall survival (mOS) durations were observed in the RASm/TP53w group (7.3 months and 16.9 months, respectively). Median OS was significantly lower in the RASm/TP53w group compared to the RASw/TP53w group (16.9 months vs. 26.0 months, p = 0.003), whereas no significant difference was found between mPFS durations. No statistically significant difference was observed between the RASw/TP53m and RASm/TP53m groups and the RASw/TP53w group for mPFS and mOS. The RASm/TP53w mutation profile was identified as an independent prognostic factor for decreased OS in the multivariate Cox regression analysis. Conclusions: In mCRC cases with the RASm/TP53w mutation profile, the mOS was significantly lower. The RASm/TP53w mutation profile was identified as an independent prognostic factor for decreased OS. These findings are expected to contribute to the literature as real-world evidence regarding the prognostic value of different RAS and TP53 mutation combinations in mCRC.
27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Aim: Breast cancer is the most frequently diagnosed cancer and one of the main causes of cancer related death in women worldwide. Around 70% of breast cancer cases are estrogen receptor positive (ER+), and many of these patients benefit from hormone based treatments. However, despite initial responses, a large number of patients eventually develop resistance, especially in the metastatic stage .This study aims to identify and analyze the 100 most cited original research articles related to ESR1-mutant breast cancer, providing insights into publication trends, leading contributors, and thematic focuses in this growing field.Material and Methods: A systematic search was conducted on May 20, 2025, using the Web of Science Core Collection (WoSCC). The top 100 cited original research articles related to ESR1 mutations in breast cancer were selected based on citation count, excluding non-original and non-English papers. Bibliometric mapping was performed using VOSviewer software (v1.6.10).Results: A total of 100 articles published between 2007 and 2024 were analyzed. The most cited article received 919 citations. Most publications and citations originated from the United States. Nature Genetics had the highest citation rate per article, while Clinical Cancer Research had the largest number of top-cited articles. Common keywords included “ESR1,” “breast cancer,” and “resistance.”Conclusion: This bibliometric analysis highlights the foundational and emerging literature on ESR1 mutations in breast cancer. It provides a valuable reference for researchers and clinicians by identifying pivotal studies and mapping the development of this research domain.
ObjectiveSoft tissue sarcoma (STS) is a rare type of cancer that has many different histological subtypes. New prognostic markers are needed to predict the prognosis of patients with metastatic disease. We aimed to investigate the prognostic importance of the systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) in patients diagnosed with metastatic STS. Material and MethodA total of eighty-eight patients were evaluated retrospectively. The SII and PIV were calculated with the blood parameters that were checked before treatment. The Kaplan-Meier method was used for survival analysis.ResultsThe median value was calculated as 1019.6 for the SII and 586.0 for the PIV. The median PFS was 7.1 months (95% CI 5.0–9.1) for PIV